Tony Keech

NHMRC Clinical trials Centre, University of Sydney



Professor Anthony Keech is a Professor of Medicine, Cardiology and Epidemiology and Consultant Cardiologist at the Royal Prince Alfred Hospital in Sydney and Deputy Director of the NHMRC Clinical Trials Centre at the University of Sydney. His specialist areas are large trials to inform treatment strategies for acute coronary syndromes, risk factor reduction in cardiovascular disease, and prevention of vascular disease including in diabetes. He also works actively in the area of neonatal health and disease in collaboration with colleagues who lead neonatal trials. He holds an NHMRC Senior Principal Research Fellowship. He also works in the areas of microvascular complications of diabetes and underlying molecular mechanisms. He is the immediate past Chairman of the Clinical Trials Working Group of the ANZ Cardiac Society and previous Secretary and Founding member of the Asia Pacific Society of Atherosclerosis and Vascular Diseases. Prof. Keech has co-authored over 185 peer-reviewed papers, which have been cited over 20,000 times and have had major impacts on clinical care and health policy. His h-index is 46. 32 papers have been cited over 100 times, and 6 papers >1000 times. Research articles are often in leading journals e.g. Lancet (22), New England J. of Medicine (2), JAMA (1). His involvement has been instrumental in landmark trials of beta-blockers, thrombolytic therapies, aspirin, magnesium, ACE-inhibitors, GPIIbIIIa inhibitor agents, statins, metformin, fenofibrate, anti-obesity agents and PCSK9 inhibitors, including through key roles in the ISIS, GUSTO, VIGOUR and TIMIS group collaborations. More recently studies in which he has contributed design and strategic input have had major impact on care in neonatology, particularly in relation to oxygen administration. He leads numerous systematic review of evidence, and his work has altered guidelines nationally and internationally and triggered new indications for cholesterol treatment and prevention of diabetic retinopathy. He has testified about clinical evidence to PBAC ,the European Medicines Agency and the US FDA on many occasions. His basic science translational research has explained mechanisms of retinal injury and protection, kidney damage and ischemic tissue injury. He is also a Foundation member of the NSW State Ethics Committee, and the Australian Clinical Trials Alliance. In 2015 he was the chair of the scientific advisory committee and convenor of ACTA 2015 International Clinical Trials Symposium which brought together 6 international speakers, 45 Australian speakers and 500 delegates. He is the director of the University of Sydney Masters in Clinical Trials Research Course. He has received more than $250M in research grant funding and numerous national and international awards and is a keen educator nationally and internationally.